Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Furthermore, the disorder is also associated with the accumulation of Lewy bodies containing a-synuclein within the substantia nigra pars compacta (Braak et al., 2003).”
BackgroundMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“This heritable form of PD is associated with earlier onset and aggressive progression (Polymeropoulos et al., 1997).”
BackgroundMerikangas, K. R., He, J.-P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L., Benjet, C., Georgiades, K., & Swendsen, J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.05.017 · Cited by 6,278
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059
Association between obesity and psychiatric disorders in the US adult population
Simon, G. E., Von Korff, M., Saunders, K., Miglioretti, D. L., Crane, P. K., van Belle, G., & Kessler, R. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.824 · Cited by 1,338
Hart, H., Radua, J., Nakao, T., Mataix-Cols, D., & Rubia, K. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.277 · Cited by 764
Gillies, G. E., & McArthur, S. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002071 · Cited by 733 · cited 1×
“PD is a neurodegenerative disorder affecting 3% of people aged $65 years (Gillies and McArthur, 2010).”
BackgroundNew Insights into the Mechanism of Action of Amphetamines
Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105140 · Cited by 731 · cited 5×
“, AMPH analogs) elevate extracellular DA levels by reversing the process of transporter-mediated exchange, thereby enhancing DA efflux (Liang and Rutledge, 1982; Jones et al., 1999; for review, also see Sulzer et al., 2005; Fleckenstein et al., 2007).”
BackgroundInfluentialSelf-citationEvaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684 · cited 1×
“Finally, evidence from brain imaging studies, albeit mixed, indicates that DAT levels and DA signaling may be altered in patients with ADHD (Dougherty et al., 1999; Krause et al., 2000; Volkow et al., 2007a,b, 2009), although other transmitter systems are also likely to play an important role.”
BackgroundMcCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · cited 2×
“, 2007), and these decreases persist for years after abstinence (McCann et al., 1998).”
BackgroundSwanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580
Krause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., & Tatsch, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01040-5 · Cited by 521 · cited 23×
“Although the etiology of the disorder is not well understood, several lines of evidence implicate dysregulation of DA systems in ADHD (for reviews, see Swanson et al., 2007; Volkow et al., 2007a,b, 2009).”
BackgroundInfluentialGill, M., Daly, G., Heron, S., Hawi, Z., & Fitzgerald, M. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000290 · Cited by 482
Figlewicz, D. P., Evans, S. B., Murphy, J., Hoen, M., & Baskin, D. G. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04087-8 · Cited by 482
Mechanisms of dopamine transporter regulation in normal and disease states
Vaughan, R. A., & Foster, J. D. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.07.005 · Cited by 419 · cited 1×
“These are not all encompassing, and the reader is referred to additional recent reviews (Sulzer et al., 2005; Alter et al., 2013; Schmitt et al., 2013; Vaughan and Foster, 2013; Howell and Negus, 2014; Nickell et al., 2014).”
BackgroundThe binding sites for cocaine and dopamine in the dopamine transporter overlap
Beuming, T., Kniazeff, J., Bergmann, M. L., Shi, L., Gracia, L., Raniszewska, K., Newman, A. H., Javitch, J. A., Weinstein, H., Gether, U., et al. (2008) · Nature Neuroscience · doi:10.1038/nn.2146 · Cited by 354
Brain Serotonin and Dopamine Transporter Bindings in Adults With High-Functioning Autism
Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.137 · Cited by 352
Volkow, N. D., Wang, G.-J., Newcorn, J., Telang, F., Solanto, M. V., Fowler, J. S., Logan, J., Ma, Y., Schulz, K., Pradhan, K., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.8.932 · Cited by 331
Brain dopamine transporter levels in treatment and drug naive adults with ADHD
Volkow, N. D., Wang, G.-J., Newcorn, J., Fowler, J. S., Telang, F., Solanto, M. V., Logan, J., Wong, C., Ma, Y., Swanson, J. M., et al. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.10.014 · Cited by 249
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243 · cited 1×
“…more effective than DA releasers for reducing use of DA releasers (Grabowski et al., 1997; Tiihonen et al., 2007), whereas DA releasers are more effective than DAT inhibitors for reducing use of DA inhibitors (Grabowski et al., 2001; Mooney et al., 2009; Longo et al., 2010; Galloway et al., 2011).”
BackgroundCognitive function and nigrostriatal markers in abstinent methamphetamine abusers
Johanson, C.-E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., Galloway, G. P., Koeppe, R. A., Kilbourn, M. R., Robbins, T., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0330-6 · Cited by 233 · cited 2×
“…abstinent METH-abusing subjects demonstrated increased VMAT2 levels in the caudate, putamen, and ventral striatum compared with control subjects (Boileau et al., 2008), and VMAT2 levels were decreased inMETH-abusing subjects that had been abstinent for at least 3 months (Johanson et al., 2006).”
BackgroundAge‐specific progression of nigrostriatal dysfunction in Parkinson's disease
de la Fuente‐Fernández, R., Schulzer, M., Kuramoto, L., Cragg, J., Ramachandiran, N., Au, W. L., Mak, E., McKenzie, J., McCormick, S., Sossi, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22284 · Cited by 222
FIORINO, D., COURY, A., FIBIGER, H., & PHILLIPS, A. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90109-4 · Cited by 131
Effects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124 · cited 1×
“…more effective than DA releasers for reducing use of DA releasers (Grabowski et al., 1997; Tiihonen et al., 2007), whereas DA releasers are more effective than DAT inhibitors for reducing use of DA inhibitors (Grabowski et al., 2001; Mooney et al., 2009; Longo et al., 2010; Galloway et al., 2011).”
BackgroundRole of monoamine transporters in mediating psychostimulant effects
Riddle, E. L., Fleckenstein, A. E., & Hanson, G. R. (2005) · The AAPS Journal · doi:10.1208/aapsj070481 · Cited by 117
Self-citationProton: substrate stoichiometries during active transport of biogenic amines in chromaffin ghosts
Johnson, R. G., Carty, S. E., & Scarpa, A. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69274-4 · Cited by 96
Amphetamine releases dopamine from synaptic vesicles by dual mechanisms
Floor, E., & Meng, L. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12963-3 · Cited by 54
Narendran, R., Lopresti, B. J., Martinez, D., Mason, N. S., Himes, M., May, M. A., Daley, D. C., Price, J. C., Mathis, C. A., & Frankle, W. G. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010126 · Cited by 53 · cited 2×
“users also have reductions in dihydrotetrabenazine binding of VMAT2 in vivo (Narendran et al., 2012).”
BackgroundAmphetamine Elicits Opposing Actions on Readily Releasable and Reserve Pools for Dopamine
Covey, D. P., Juliano, S. A., & Garris, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060763 · Cited by 49
Cited by
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Impaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
“Alterations in SV pH or H-ATPase activity lead to ineffective VMAT2 activity and quantal size of DA release.(10,112) Disruption of this pH gradient might also occur through mitochondrial dysfunction as it requires ATP.”
BackgroundAlkam, T., Mamiya, T., Kimura, N., Yoshida, A., Kihara, D., Tsunoda, Y., Aoyama, Y., Hiramatsu, M., Kim, H.-C., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4591-z · Cited by 50
Metadata
- Authors
- German, C. L., Baladi, M. G., McFadden, L. M., Hanson, G. R., & Fleckenstein, A. E.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 67
- Issue
- 4
- Pages
- 1005-1024
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2133828007
- Cited by
- 197
- References
- 32
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.